Edgewise Therapeutics
Clinical trials sponsored by Edgewise Therapeutics, explained in plain language.
Edgewise Therapeutics
EWTX
NASDAQ
A clinical-stage biopharmaceutical company developing muscle disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to slow muscle damage in becker MD Results expected Sep 2026 (estimated)
- New drug trial hopes to slow muscle damage in kids with DMD Results expected Jan 2027 (estimated)
- New hope for duchenne kids: drug combo after gene therapy tested Results expected Mar 2027 (estimated)